Silk Road Medical shares are trading lower after the company announced preliminary Q3 revenue results below estimates and issued FY23 revenue guidance below estimates.
Portfolio Pulse from Benzinga Newsdesk
Silk Road Medical has announced preliminary Q3 revenue results that are below estimates. The company also issued FY23 revenue guidance that is lower than expected.
October 11, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Silk Road Medical's stock is trading lower due to disappointing Q3 revenue results and lower than expected FY23 revenue guidance.
Silk Road Medical's stock is likely to be negatively impacted in the short term due to the company's lower than expected Q3 revenue results and FY23 revenue guidance. This news indicates a potential slowdown in the company's growth, which could lead to a decrease in investor confidence and a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100